Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
venerdì, ottobre 02
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Corvus Pharmaceuticals Inc
CRVS
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$11.00
0.07
0.64%
Ult. Agg.: Oct 2, 8:16 AM
$11.00
0.07
0.64%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Corvus Pharmaceuticals Financials
Corvus Pharmaceuticals (CRVS) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Corvus Pharma Q2 EPS $(0.19) Misses $(0.17) Estimate
Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.17) by 11.76 percent. This is a 90 percent decrease over losses of $(0.10) per share from the
Benzinga Newsdesk
PRO
Corvus Pharma Q1 EPS $(0.15), Inline
Benzinga Newsdesk
PRO
Corvus Pharma Q4 EPS $(0.15) Misses $(0.13) Estimate
Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.13) by 15.38 percent. This is a 16.67 percent increase over losses of $(0.18) per share from
Benzinga Newsdesk
Earnings Scheduled For March 12, 2026
Benzinga Insights
PRO
Corvus Pharma Q3 EPS $(0.12) Beats $(0.14) Estimate
Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 12.41 percent. This is a 80 percent increase over losses of $(0.60) per share from the
Benzinga Newsdesk
Earnings Scheduled For November 4, 2025
Benzinga Insights
